A detailed history of Daiwa Securities Group Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 18,006 shares of BMRN stock, worth $1.18 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
18,006
Previous 16,821 7.04%
Holding current value
$1.18 Million
Previous $1.39 Million 8.59%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$69.02 - $93.84 $81,788 - $111,200
1,185 Added 7.04%
18,006 $1.27 Million
Q2 2024

Aug 07, 2024

BUY
$74.43 - $92.22 $38,257 - $47,401
514 Added 3.15%
16,821 $1.39 Million
Q1 2024

May 02, 2024

SELL
$83.81 - $99.0 $292,580 - $345,609
-3,491 Reduced 17.63%
16,307 $1.42 Million
Q4 2023

Jan 31, 2024

BUY
$76.22 - $98.51 $28,887 - $37,335
379 Added 1.95%
19,798 $1.91 Million
Q3 2023

Nov 01, 2023

SELL
$85.07 - $94.48 $27,988 - $31,083
-329 Reduced 1.67%
19,419 $1.72 Million
Q2 2023

Jul 31, 2023

BUY
$86.68 - $100.3 $16,122 - $18,655
186 Added 0.95%
19,748 $1.71 Million
Q1 2023

May 02, 2023

SELL
$87.74 - $117.27 $32,288 - $43,155
-368 Reduced 1.85%
19,562 $1.9 Million
Q4 2022

Feb 06, 2023

SELL
$80.93 - $108.63 $586,418 - $787,132
-7,246 Reduced 26.66%
19,930 $2.06 Million
Q3 2022

Nov 02, 2022

BUY
$82.16 - $96.94 $655,965 - $773,968
7,984 Added 41.6%
27,176 $2.3 Million
Q2 2022

Aug 09, 2022

BUY
$71.48 - $86.85 $6,862 - $8,337
96 Added 0.5%
19,192 $1.59 Million
Q1 2022

Apr 29, 2022

BUY
$74.28 - $92.69 $236,878 - $295,588
3,189 Added 20.05%
19,096 $1.47 Million
Q4 2021

Feb 03, 2022

SELL
$71.72 - $91.47 $40,880 - $52,137
-570 Reduced 3.46%
15,907 $1.41 Million
Q3 2021

Nov 05, 2021

BUY
$74.77 - $85.47 $137,950 - $157,692
1,845 Added 12.61%
16,477 $1.27 Million
Q2 2021

Aug 06, 2021

SELL
$75.51 - $84.79 $47,571 - $53,417
-630 Reduced 4.13%
14,632 $1.22 Million
Q1 2021

May 03, 2021

SELL
$74.73 - $90.69 $106,639 - $129,414
-1,427 Reduced 8.55%
15,262 $1.15 Million
Q4 2020

Feb 04, 2021

BUY
$72.61 - $90.2 $387,810 - $481,758
5,341 Added 47.07%
16,689 $1.46 Million
Q3 2020

Nov 02, 2020

BUY
$71.87 - $131.03 $173,709 - $316,699
2,417 Added 27.06%
11,348 $863,000
Q2 2020

Aug 11, 2020

SELL
$79.55 - $124.22 $797,886 - $1.25 Million
-10,030 Reduced 52.9%
8,931 $755,000
Q1 2020

May 14, 2020

BUY
$71.37 - $96.85 $269,064 - $365,124
3,770 Added 24.82%
18,961 $1.6 Million
Q4 2019

Jan 31, 2020

SELL
$64.27 - $86.37 $593,147 - $797,108
-9,229 Reduced 37.79%
15,191 $1.28 Million
Q3 2019

Nov 04, 2019

BUY
$67.4 - $85.11 $539,402 - $681,135
8,003 Added 48.75%
24,420 $1.65 Million
Q2 2019

Jul 24, 2019

SELL
$80.35 - $93.9 $99,071 - $115,778
-1,233 Reduced 6.99%
16,417 $1.41 Million
Q1 2019

Apr 26, 2019

BUY
$84.2 - $98.62 $78,558 - $92,012
933 Added 5.58%
17,650 $1.57 Million
Q4 2018

Feb 05, 2019

BUY
$80.14 - $106.07 $773,351 - $1.02 Million
9,650 Added 136.55%
16,717 $1.42 Million
Q3 2018

Nov 01, 2018

BUY
$93.92 - $105.72 $28,176 - $31,716
300 Added 4.43%
7,067 $685,000
Q1 2018

May 02, 2018

BUY
$77.67 - $92.63 $121,708 - $145,151
1,567 Added 30.13%
6,767 $549,000
Q3 2017

Nov 02, 2017

BUY
$80.6 - $94.95 $419,119 - $493,740
5,200
5,200 $484,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.2B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.